2010-0145 - PLCO - The Cancer Data Access System

Explore PLCO

PLCO Home
Learn about PLCO
PLCO Datasets
Approved Projects
Publications
Contact Us

Begin a Data-Only Project
Begin an Images Project
Begin an EEMS Biospecimens Application
Begin a Request Form for Specimen Verification (PAR-21-330)

(More)

Latest PLCO News

Aug 16, 2024 Accepting Requests for Specimen Verification for FOA (PAR-21-330) from Aug. 15, 2024 to Sept. 12, 2024 Dec 22, 2023 Accepting Requests for Specimen Verification for FOA (PAR-21-330) from Dec. 15, 2023 to January 12, 2024

View 0 Studies Requested

Browse Lab Results > 2010-0145

Summary Tab
Datasets Tab

Trial Summary

About CDAS Project, PI, Publications: A prospective study of immunologic markers and risk of lymphoid malignancies

Datasets

2010-0145 MM MGUS

Site: Lymphoid

Inclusion Criteria:

No Rare Cancers in Controls
Serum Available
Pre-Diagnostic Serum Available
Pre-Diagnostic Serum Available in Preferred Study Year

Matching Factors:

Gender
Race (W/B/O)
Study year of draw
Age at draw (+/- 2 years)
Date of draw (+/- 365 days)
Number of thaws

Match Ratio: 1:1

Match Technique: Individual matching only non-cases as controls.

Additional Matching Comments: Study year and date of draw loosened, where needed, to complete matching. One case diagnosed very late was matched to a control with slightly less followup.

Analytes:

Angiopoietin-2
B-Cell Attracting Chemokine 1
Basic Fibroblast Growth Factor
Basic fibroblast growth factor alpha 17
Bone morphogenetic protein
CD27
CD30
Chemokine (C-C Motif) Ligand 13
Chemokine (C-C Motif) Ligand 2
Chemokine (C-C Motif) Ligand 21
Chemokine (C-C Motif) Ligand 22
Chemokine (C-C Motif) Ligand 27
Chemokine (C-C Motif) Ligand 8
Chemokine (C-X-C Motif) Ligand 1
Chemokine (C-X-C Motif) Ligand 10
Chemokine (C-X-C Motif) Ligand 12
Chemokine (C-X-C Motif) Ligand 5
Endoglin
Endothelin 1
Eotaxin
Eotaxin-2
Epidermal Growth Factor
Epidermal growth factor alpha 17
Follistatin
Granulocyte-Colony Stimulating Factor
Granulocyte-Colony Stimulating Factor alpha 17
Heparin-binding EGF-like growth factor
Heparin-binding growth factor 1
Hepatocyte Growth Factor
Interleukin 1 Receptor Antagonist
Interleukin 16
Interleukin 3
Interleukin 33
Interleukin 7
Interleukin 8
Interleukin 8 alpha 17
Leptin
Macrophage Inflammatory Protein 1 delta
Macrophage inflammatory protein 1 beta
Placental Growth Factor
Stem Cell Factor
Thrombopoietin
Thymic Stromal Lymphopoietin
Thymus and Activation Regulated Chemokine
Transforming Growth Factor Alpha
Tumor Necrosis Factor Alpha 1
Tumor Necrosis Factor Beta
Tumor Necrosis Factor Receptor Superfamily, Member 10
Vascular Endothelial Growth Factor
Vascular endothelial growth factor A
Vascular endothelial growth factor C
Vascular endothelial growth factor D

Number of Cases: 764

Number of Controls: 256

Site: Lymphoid

Inclusion Criteria:

No Rare Cancers in Controls
Serum Available
Pre-Diagnostic Serum Available
Pre-Diagnostic Serum Available in Preferred Study Year

Matching Factors:

Gender
Race (W/B/O)
Study year of draw
Age at draw (+/- 2 years)
Date of draw (+/- 365 days)
Number of thaws

Match Ratio: 1:1

Match Technique: Individual matching only non-cases as controls.

Additional Matching Comments: Study year and date of draw loosened, where needed, to complete matching. One case diagnosed very late was matched to a control with slightly less followup.

Analytes:

Angiopoietin-2
B-Cell Attracting Chemokine 1
Basic Fibroblast Growth Factor
Basic fibroblast growth factor alpha 17
Bone morphogenetic protein
CD27
CD30
Chemokine (C-C Motif) Ligand 13
Chemokine (C-C Motif) Ligand 2
Chemokine (C-C Motif) Ligand 21
Chemokine (C-C Motif) Ligand 22
Chemokine (C-C Motif) Ligand 27
Chemokine (C-C Motif) Ligand 8
Chemokine (C-X-C Motif) Ligand 1
Chemokine (C-X-C Motif) Ligand 10
Chemokine (C-X-C Motif) Ligand 12
Chemokine (C-X-C Motif) Ligand 5
Endoglin
Endothelin 1
Eotaxin
Eotaxin-2
Epidermal Growth Factor
Epidermal growth factor alpha 17
Follistatin
Granulocyte-Colony Stimulating Factor
Granulocyte-Colony Stimulating Factor alpha 17
Heparin-binding EGF-like growth factor
Heparin-binding growth factor 1
Hepatocyte Growth Factor
Interleukin 1 Receptor Antagonist
Interleukin 16
Interleukin 3
Interleukin 33
Interleukin 7
Interleukin 8
Interleukin 8 alpha 17
Leptin
Macrophage Inflammatory Protein 1 delta
Macrophage inflammatory protein 1 beta
Placental Growth Factor
Stem Cell Factor
Thrombopoietin
Thymic Stromal Lymphopoietin
Thymus and Activation Regulated Chemokine
Transforming Growth Factor Alpha
Tumor Necrosis Factor Alpha 1
Tumor Necrosis Factor Beta
Tumor Necrosis Factor Receptor Superfamily, Member 10
Vascular Endothelial Growth Factor
Vascular endothelial growth factor A
Vascular endothelial growth factor C
Vascular endothelial growth factor D

Number of Cases: 764

Number of Controls: 256

2010-0145 Primary

Site: Lymphoid

Inclusion Criteria:

No Cancer Prior to Randomization
No Rare Cancer
With Consent (ESC1)
With Perfect T0 Serum
Selected Subjects
Adjustments for Batching

Matching Factors:

Age at Randomization (5 year intervals)
Race
Gender
Study Center
Entry Season/Year
Time of Blood Draw (am/pm)
Exit Date

Match Ratio: 1 to 1

Match Technique: Individual matching only non-cases as controls.

Analytes:

Amylin
B-Cell Attracting Chemokine 1
Basic Fibroblast Growth Factor
C-Peptide
Chemokine (C-C Motif) Ligand 13
Chemokine (C-C Motif) Ligand 19
Chemokine (C-C Motif) Ligand 2
Chemokine (C-C Motif) Ligand 20
Chemokine (C-C Motif) Ligand 21
Chemokine (C-C Motif) Ligand 22
Chemokine (C-C Motif) Ligand 27
Chemokine (C-C Motif) Ligand 8
Chemokine (C-X-C Motif) Ligand 1
Chemokine (C-X-C Motif) Ligand 10
Chemokine (C-X-C Motif) Ligand 11
Chemokine (C-X-C Motif) Ligand 12
Chemokine (C-X-C Motif) Ligand 5
Chemokine (C-X-C Motif) Ligand 6
Chemokine (C-X-C Motif) Ligand 9
Chemokine (C-X3-C Motif) Ligand 1
Chemokine Ligand 7
Eotaxin
Eotaxin-2
Epidermal Growth Factor
Fms-related tyrosine kinase 3 ligand
Gastric inhibitory polypeptide
Glucagon
Glucagon-like peptide-1
Granulocyte-Colony Stimulating Factor
Granulocyte-Macrophage Colony Stimulating Factor
Insulin
Interferon alpha-2
Interferon-gamma
Interleukin 1
Interleukin 1 Receptor Antagonist
Interleukin 1 alpha
Interleukin 1 beta
Interleukin 10
Interleukin 11
Interleukin 12 p40
Interleukin 12 p70
Interleukin 15
Interleukin 16
Interleukin 17
Interleukin 2
Interleukin 29
Interleukin 3
Interleukin 33
Interleukin 4
Interleukin 5
Interleukin 6
Interleukin 7
Interleukin 8
Leptin
Leukemia Inhibitory Factor
Macrophage Inflammatory Protein 1 alpha
Macrophage Inflammatory Protein 1 delta
Macrophage inflammatory protein 1 beta
Pancreatic Polipeptide
Pancreatic Polipeptide YY
Soluble Epidermal Growth Factor Receptor
Soluble Interleukin 1 Receptor Type 1
Soluble Interleukin 2 Receptor Alpha
Soluble Interleukin 4 Receptor
Soluble Interleukin 6 Receptor
Soluble Interleukin 6 beta
Soluble Receptor for Advanced Glycation Endproducts
Soluble Tumor Necrosis Factor Receptor I
Soluble Tumor Necrosis Factor Receptor II
Stem Cell Factor
Thrombopoietin
Thymic Stromal Lymphopoietin
Thymus and Activation Regulated Chemokine
Transforming Growth Factor Alpha
Tumor Necrosis Factor Alpha 1
Tumor Necrosis Factor Beta
Tumor Necrosis Factor Receptor Superfamily, Member 10
Tumor Necrosis Factor Receptor Superfamily, Member 5
Tumor Necrosis Factor Receptor Superfamily, Member 8
Vascular Endothelial Growth Factor
Vascular endothelial growth factor receptor 1
Vascular endothelial growth factor receptor 2
Vascular endothelial growth factor receptor 3

Number of Cases: 307

Number of Controls: 307

Site: Lymphoid

Inclusion Criteria:

No Cancer Prior to Randomization
No Rare Cancer
With Consent (ESC1)
With Perfect T0 Serum
Selected Subjects
Adjustments for Batching

Matching Factors:

Age at Randomization (5 year intervals)
Race
Gender
Study Center
Entry Season/Year
Time of Blood Draw (am/pm)
Exit Date

Match Ratio: 1 to 1

Match Technique: Individual matching only non-cases as controls.

Analytes:

Amylin
B-Cell Attracting Chemokine 1
Basic Fibroblast Growth Factor
C-Peptide
Chemokine (C-C Motif) Ligand 13
Chemokine (C-C Motif) Ligand 19
Chemokine (C-C Motif) Ligand 2
Chemokine (C-C Motif) Ligand 20
Chemokine (C-C Motif) Ligand 21
Chemokine (C-C Motif) Ligand 22
Chemokine (C-C Motif) Ligand 27
Chemokine (C-C Motif) Ligand 8
Chemokine (C-X-C Motif) Ligand 1
Chemokine (C-X-C Motif) Ligand 10
Chemokine (C-X-C Motif) Ligand 11
Chemokine (C-X-C Motif) Ligand 12
Chemokine (C-X-C Motif) Ligand 5
Chemokine (C-X-C Motif) Ligand 6
Chemokine (C-X-C Motif) Ligand 9
Chemokine (C-X3-C Motif) Ligand 1
Chemokine Ligand 7
Eotaxin
Eotaxin-2
Epidermal Growth Factor
Fms-related tyrosine kinase 3 ligand
Gastric inhibitory polypeptide
Glucagon
Glucagon-like peptide-1
Granulocyte-Colony Stimulating Factor
Granulocyte-Macrophage Colony Stimulating Factor
Insulin
Interferon alpha-2
Interferon-gamma
Interleukin 1
Interleukin 1 Receptor Antagonist
Interleukin 1 alpha
Interleukin 1 beta
Interleukin 10
Interleukin 11
Interleukin 12 p40
Interleukin 12 p70
Interleukin 15
Interleukin 16
Interleukin 17
Interleukin 2
Interleukin 29
Interleukin 3
Interleukin 33
Interleukin 4
Interleukin 5
Interleukin 6
Interleukin 7
Interleukin 8
Leptin
Leukemia Inhibitory Factor
Macrophage Inflammatory Protein 1 alpha
Macrophage Inflammatory Protein 1 delta
Macrophage inflammatory protein 1 beta
Pancreatic Polipeptide
Pancreatic Polipeptide YY
Soluble Epidermal Growth Factor Receptor
Soluble Interleukin 1 Receptor Type 1
Soluble Interleukin 2 Receptor Alpha
Soluble Interleukin 4 Receptor
Soluble Interleukin 6 Receptor
Soluble Interleukin 6 beta
Soluble Receptor for Advanced Glycation Endproducts
Soluble Tumor Necrosis Factor Receptor I
Soluble Tumor Necrosis Factor Receptor II
Stem Cell Factor
Thrombopoietin
Thymic Stromal Lymphopoietin
Thymus and Activation Regulated Chemokine
Transforming Growth Factor Alpha
Tumor Necrosis Factor Alpha 1
Tumor Necrosis Factor Beta
Tumor Necrosis Factor Receptor Superfamily, Member 10
Tumor Necrosis Factor Receptor Superfamily, Member 5
Tumor Necrosis Factor Receptor Superfamily, Member 8
Vascular Endothelial Growth Factor
Vascular endothelial growth factor receptor 1
Vascular endothelial growth factor receptor 2
Vascular endothelial growth factor receptor 3

Number of Cases: 307

Number of Controls: 307

The following datasets contain the data available for 2010-0145. The description and documentation for each file is listed below. SAS7bdat and CSV versions of the actual data will be available to CDAS projects approved to use this data.

Datasets

Files	Description
Data Dictionary (PDF - 204.5 KB)	1. The 2010-0145 MM MGUS dataset contains results from 764 cases and 256 controls.
Data Dictionary (PDF - 250.6 KB)	2. The 2010-0145 Primary dataset contains results from 307 cases and 307 controls.